Special Issue "New Advances in Clinical and Translational Breast Cancer Research"
Deadline for manuscript submissions: 25 July 2022 | Viewed by 493
Interests: breast cancer; biomarker research; translational research; endocrine therapy resistance
Despite significant improvements in breast cancer management and prognosis in recent decades, it remains the most common cancer and the leading cause of cancer-related death in women worldwide. The many remaining challenges include the need for better patient stratification and the development of resistance to different treatment modalities; a better understanding of the heterogenous biology of the disease and the complex mechanisms enabling cancer relapse and progression will be essential to continue improving breast cancer outcomes, especially in the metastatic setting.
In addition to clinical studies, translational research—which utilises clinical samples and data for discovery and validation studies, and/or seeks to answer specific clinical questions—will be essential in addressing these needs and, crucially, bringing novel findings or emerging treatments closer to the clinic.
In this Special Issue, we will collect original research articles and reviews that report on or summarise the latest findings in clinical and translational breast cancer research. Such studies can lead to the identification or validation of novel biomarkers or potential therapeutic targets, the characterisation of the effects of emerging therapeutics or the development of predictive tools with clinical potential. Additionally, the study of clinical specimens can help shed light on the complexity of the disease, both identifying disease mechanisms or corroborating findings based on pre-clinical cancer models.
Dr. Carlos Martínez-Pérez
Dr. Arran K. Turnbull
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- breast cancer
- clinical research
- translational research
- emerging therapies
- novel drugs
- personalized medicine
- biomarker research
- biomarker discovery